

CLINICAL TRIALS

BREAST CANCER

20210 - Breast Cancer Index (BCI) Registry Study. Testing to see if patient would benefit for 10 years of hormone therapy instead of 5years. [Breast Cancer Index \(BCI\) Registry - Full Text View - ClinicalTrials.gov](#)

17079 - MammaPrint, Blueprint, and Full-Genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry) <https://clinicaltrials.gov/ct2/show/NCT03053193>

20326 - A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA) [Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer - Full Text View - ClinicalTrials.gov](#)

22018- A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171) [A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer \(evERA Breast Cancer\) - Full Text View - ClinicalTrials.gov](#)

MULTIPLE DISEASES

21270 - A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 | GOG 3066) [A Study of ZN-c3 in Subjects With Malignant Tumors - Full Text View - ClinicalTrials.gov](#)

FIRST LINE METASTATIC PANCREATIC CANCER

21235 - A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301) [Study of Efficacy and Safety of NIS793 in Combination With Standard of Care \(SOC\) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma \(mPDAC\) - daNIS-2 - Full Text View - ClinicalTrials.gov](#)

BLADDER CANCER

20402 - A phase 3 randomized study of Atezolizumab versus placebo as adjuvant therapy in patients with High-Risk Muscle Invasive Bladder Cancer who are CTDNA-Positive following cystectomy. <https://clinicaltrials.gov/ct2/show/NCT04660344>

NON-SMALL CELL LUNG CANCER

21541- A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS \geq 50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations) [Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations - Full Text View - ClinicalTrials.gov](#)

STAGE III NON-SMALL CELL LUNG CANCER

20137 - A Phase 3 Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum Based Chemoradiation. <https://clinicaltrials.gov/ct2/show/NCT04294810>

FIRST LINE NON-SMALL CELL LUNG CANCER- LOCALLY ADVANCED OR METASTATIC

20423 - A randomized Trial of Tomivosertib in Combination with Anti-PD-(L)1 Therapy in Subjects with Non-Small Cell Lung Cancer as First Line Therapy or When Progressing on Single Agent First Line Anti-PD-(L)1 Therapy. <https://clinicaltrials.gov/ct2/show/NCT04622007>

ON HOLD

Metastatic Non-Squamous, Non-Small Cell Lung Cancer

A Study Evaluating the Safety, Tolerability, and Efficacy of AMG510 Alone or in Combination with Pembrolizumab, With or Without Chemotherapy, in Subjects with Metastatic Non-Squamous, Non-Small Cell Lung Cancer with KRASp.12C Mutation. [Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy - Full Text View - ClinicalTrials.gov](#)

OTHER TRIALS MAY BE AVAILABLE, PLEASE CALL TO INQUIRE:

Deborah Schmitt, RN, OCN
Palm Bay Clinical Research Nurse
20 San Filippo SE, Palm Bay, FL 32909
(321) 405-1022
Deborah.Schmitt@usoncology.com

Kim Dean, RN, BSN, OCN
Eau Gallie Clinical Research Nurse
2290 W Eau Gallie Blvd, Melbourne, FL 32935
(321) 254-4776
Kim.Dean@usoncology.com